Biosimilars Bandwagon Builds
Baxter, Momenta Ink Potential $470M Partnership for Six FOBs
By Marie Powers
Wednesday, December 28, 2011
Baxter International Inc. and Momenta Pharmaceuticals Inc. jumped on the biosimilars bandwagon with a global collaboration to develop and commercialize up to six follow-on biologics (FOBs).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.